A Phase 1 study of Alectinib and Duvelisib in ALK+ ALCL

Study Description

A Study of Combination Treatment with Alectinib and Duvelisib for Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma

Study Details

Registry ID:

NCT07001384

Conditions:

Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma

Phase:

Phase 1

Target Enrollment:

30 participants

Start Date:

August 8, 2025

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (7 sites)

• Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
  Commack, New YorkUnited States, United States
• Memorial Sloan Kettering Nassau (Limited Protocol Activities)
  Uniondale, New YorkUnited States, United States
• Memorial Sloan Kettering Westchester (Limited Protocol Activities)
  Harrison, New YorkUnited States, United States
• Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
  Middletown, New JerseyUnited States, United States
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New YorkUnited States, United States
• Memorial Sloan Kettering Bergen (Limited Protocol Activities)
  Montvale, New JerseyUnited States, United States
• Memorial Sloan Kettering Basking Ridge (LimitedProtocol Activities)
  Basking Ridge, New JerseyUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →